Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8178-8183

  Wagner, Stefan ^a   Krepler, Clemens ^b   Allwardt, Dorothee ^a   Latzka, Julia ^a   Strommer, Sabine ^b   Scheiner, Otto ^a   Pehamberger, Hubert ^b   Wiedermann, Ursula ^a   Hafner, Christine ^b   Breiteneder, Heimo ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; MELANOMA VACCINE; MIMOTOPE 225D9.2 ANTIGEN; UNCLASSIFIED DRUG; CANCER ANTIBODY; CANCER VACCINE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INFILTRATION; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; INOCULATION; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR VOLUME; VACCINATION; XENOTRANSPLANTATION; ANIMAL; CANCER TRANSPLANTATION; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; MOLECULAR WEIGHT; MOUSE MUTANT; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, SCID; MOLECULAR WEIGHT; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 58149355767     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0371     Document Type: Article

References (25)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19: 3622-34.
2. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfateproteogly-can (MSCP) with biological and clinical significance. Crit Rev Immunol 2004;24:267-96.
3. Bumol TF, Wang QC, Reisfeld RA, Kaplan NO. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci USA 1983;80:529-33.
4. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:466-70.
5. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 1994;54:415-21.
6. Bender H, Grapow M, Schomburg A, Reinhold U, Biersack HJ. Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. Hybridoma1997;16:65 -8.
7. Hafner C, Breiteneder H, Ferrone S, et al. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 2005;114:426 -32.
8. Wagner S, Hafner C, Allwardt D, et al. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 2005;174:976 -82.
9. Popkov M, Sidrac-Ghali S, Alakhov V, Mandeville R. Epitope-specific antibody response to HT-1080 fibrosarcoma cells by mimotope immunization. Clin Cancer Res 2000;6:3629 -35.
10. Riemer AB, Klinger M, Wagner S, et al. Generation of peptide mimics of the epitope recognized bytrastuzumab on the oncogenic protein HER-2/neu. J Immunol 2004;173:394-401.
11. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005;97:1663 -70.
12. Wagner S, Jasinska J, Breiteneder H, et al. Delayed tumor onset and reduced tumor growth progression after immunization with a HER-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat 2007;106:29 -38.
13. Geysen HM, Barteling SJ, Meloen RH. Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein. Proc Natl Acad Sci USA 1985;82:178-82.
14. Kieber-EmmonsT, Luo P, Qiu J, et al. Vaccination with carbohydrate peptide mimotopes promotes antitumor responses. Nat Biotechnol 1999;17:660-5.
15. Hafner C, Wagner S, Jasinska J, et al. Epitopespecific antibody response to Mel-CAM induced by mimotope immunization. J Invest Dermatol 2005; 124:125-31.
16. Monzavi-Karbassi B, Artaud C, Jousheghany F, et al. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol 2005;174:7057 -65.
17. Bramswig KH, Knittelfelder R, Gruber S, et al. Immunization with mimotopes prevents growth of carci-noembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res 2007;13:6501 -8.
18. 2-Microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003;171:1918-26.
19. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically activelinear and cyclicpeptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingo-myelinase- likephosphodiesterase3b precursor. Blood 2006;107:1070-7.
20. Larralde OG, Martinez R, Camacho F, et al. Identification of hepatitis A virus mimotopes by phage display, antigenicity and immunogenicity. J Virol Methods 2007;140:49 -58.
21. Beenhouwer DO, May RJ,Valadon P, Scharff MD. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library. J Immunol 2002;169:6992-9.
22. Hou Y, Gu XX. Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates. J Immunol 2003; 170:4373-9.
23. Ganglberger E, Barbara S, Scholl I, et al. Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy. FASEB J 2001;15:2524-6.
24. Hardy B, Raiter A. A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody. Vaccine 2005;23:4283 -91.
25. Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 2006;176:6046-54.